The purpose of this study is to compare the onset time and severity of dyskinesia in amantadine or Dopamine agonist initial treated groups in Parkinson's disease.
1. Dopamine agonist can delay the risk of dyskinesia by initiating treatment rather than levodopa. Amantadine is typical antidyskinetic drug. There is no data about comparison of risk of dyskinesia in amantadine and dopamine agonist by initiating treatment. 2. Prospective , randomized, open label study compare the onset time and severity of dyskinesia between groups randomized assigned order of amantadine and dopamine agonist
Study Type
OBSERVATIONAL
Enrollment
500
Beom S Jeon
Seoul, South Korea
RECRUITINGdyskinesia onset
observe duration of onset of dyskinesia from initial treatment observe until 10 years
Time frame: up to 10 years from the start of durg (Amantadine or dopaimine agonsit)
UPDRS, severity of dyskinesia between groups
observe duration of onset of dyskinesia from initial treatment observe until 10 years compare the UPDRS and severity of dyskinesia between groups
Time frame: observe duration of onset of dyskinesia from initial treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.